Wednesday, 1 August 2012

Clinical Development-Rheumatoid Arthritis-Israeli Company-Positive Data-Psoriasis

Israel's Can-Fite sees positive data for psoriasis drug

TEL AVIV (Reuters) - Can-Fite BioPharma expects to publish positive data at the end of the third quarter regarding the safety and efficacy of its CF101 drug under development for the treatment of Psoriasis, the Israeli company's acting CEO said on Wednesday. CF101, a small molecule oral drug, is in advanced clinical development for the treatment of autoimmune inflammatory diseases such as psoriasis, which affects the skin, and rheumatoid arthritis. ... read more..

No comments:

Post a comment